Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pfizer expands NicOx alliance
March 6, 2006
| A version of this story appeared in
Volume 84, Issue 10
In a deal valued at up to $356 million, NicOx has granted Pfizer exclusive rights to use its nitric oxide-donating technology for the discovery and development of ophthalmology products. In the first year of the pact, Pfizer will make a $27 million payment to NicOx, which includes an $18 million stake in the French biotech firm. Each year thereafter, NicOx will receive another $3.6 million in research funding, in addition to possible milestone payments and royalties. The deal builds on an existing relationship between the companies.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter